Showing 4121-4130 of 4164 results for "".
- Regenxbio Completes Dosing of Fourth Cohort in Phase 1 Trial of RGX-314 Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-dosing-of-fourth-cohort-in-phase-1-trial-of-rgx-314-gene-therapy-for-wet-amd/2479815/Regenxbio announced it has completed dosing of the fourth cohort of six patients in a phase 1 clinical trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (AMD). A total of 24 subjects have been dosed in the trial. The company also announced that an updated summary
- Eyenuk Expands into Germany with Launch of EyeArt Artificial Intelligence Eye Screening for Diabetic Retinopathyhttps://modernod.com/news/eyenuk-expands-into-germany-with-launch-of-eyeart-artificial-intelligence-eye-screening-for-diabetic-retinopathy/2479826/Eyenuk announced its expansion into Germany with the adoption of EyeArt artificial intelligence (AI) technology for the screening of diabetic retinopathy at Diabetes Center Mergentheim in Bad Mergentheim, Germany. The center is the first dedicated diabetic clinic in Germany to use artificial inte
- Ellex 2RT Retinal Rejuvenation Effective for Select Cases of Intermediate AMDhttps://modernod.com/news/ellex-2rt-retinal-rejuvenation-effective-for-select-cases-of-intermediate-amd/2479852/Ellex Medical Lasers Limited announced the results of the Ellex 2RT Laser Intervention in Age-Related Macular Degeneration (LEAD) multicenter clinical trial. The results of the trial were published in Ophthalmology. According to researchers involved in the LEAD trial, Ellex’s 2RT
- Excel-Lens Announces CE Mark Approval for CAPSULaser Selective Laser Capsulotomy (SLC) Devicehttps://modernod.com/news/excel-lens-announces-ce-mark-approval-for-capsulaser-selective-laser-capsulotomy-slc-device/2479872/Excel-Lens announced the CE mark approval of CAPSULaser, a selective laser that creates a capsulotomy during cataract surgery in just over a second. The laser energy is delivered in a continuous manner rather than a pulsed beam which can create tissue bridges. In clinical studies, CAPSULas
- RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarringhttps://modernod.com/news/rxi-pharmaceuticals-announces-positive-results-from-phase-1-2-trial-with-rxi-109-for-retinal-scarring/2479959/RXi Pharmaceuticals announced positive results with RXI-109 in a phase 1/2 clinical trial. RXI-109-1501 is an open-label, multidose, dose escalation study with three dose cohorts, enrolled sequentially, evaluating the safety and tolerability of RXI-109 injections in the eye of subjects with advan
- Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertensionhttps://modernod.com/news/nicox-initiates-phase-2-study-of-ncx-470-in-open-angle-glaucoma-and-ocular-hypertension/2479962/Nicox announced the initiation of a phase 2 clinical study evaluating NCX 470, its novel, second-generation nitric oxide (NO)-donating prostaglandin analog, for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension by enrolling 10 patient
- EyeSouth Partners Develops of Physician Advisory Boardhttps://modernod.com/news/eyesouth-partners-develops-of-physician-advisory-board/2480041/As part of its continuing focus on the highest quality patient outcomes, EyeSouth Partners, a network of integrated eye care practices located throughout the Southeast, announced the formation of its physician advisory board. Its responsibilities will include overseeing clinical policies and proc
- New Acucela Data on the Effect of Emixustat Hydrochloride on Retinal Thickness in Diabetic Retinopathyhttps://modernod.com/news/new-acucela-data-on-the-effect-of-emixustat-hydrochloride-on-retinal-thickness-in-diabetic-retinopathy/2480075/Acucela announced new data on the effect of emixustat hydrochloride on retinal thickness in diabetic retinopathy (DR). The study (protocol 4429-203) is a randomized, placebo-controlled, phase 2 clinical trial exploring the effect of oral emixustat hydrochloride in a proliferative diabetic
- Nexy Robotic Retinal Imaging System Receives FDA Clearancehttps://modernod.com/news/nexy-robotic-retinal-imaging-system-receive-fda-clearance/2480097/Konan Medical USA announced that the Nexy retinal camera received FDA 510(k) clearance and is now available in the United States. The Nexy features fully robotic operation and is designed for use in ophthalmology, optometry, hospitals, clinics and many other point-of-servic
- Orasis Pharmaceuticals Closes $13 Million Series B Financinghttps://modernod.com/news/orasis-pharmaceuticals-closes-13-million-series-b-financing/2480119/Privately-held Orasis Pharmaceuticals announced the closing of a $13 million Series B financing to be used to advance Orasis’s lead product candidate, CSF-1, an eye drop being developed for the treatment of presbyopia symptoms, through completion of its phase 2b clinical trial. The proceeds will